Accelerate Drug Discovery and Development

Accelerate Drug Discovery and Development

Industry-approved fluidic-free standard for label-free molecular interaction analysis


Written bySartorius
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00

Most assays with fluorescent or radioactive labels are endpoint assays, meaning the data is relevant to only one point in time—usually the end of the assay. Such assays mask the complexity of a binding interaction providing limited drug candidate characteristics, target binding or analyte concentration and quality. Analytical techniques that measure protein quantity and quality are used in nearly all stages of research, process development, and manufacturing of biotherapeutics. Despite their many limitations, ELISA assays have been used for decades for affinity measurements and protein quantitation in physiological and process samples.

Download the resource to learn how Octet® BLI Instruments overcome analytical challenges, courtesy of Sartorius.

Loading Next Article...
Loading Next Article...

CURRENT ISSUE - October 2025

Turning Safety Principles Into Daily Practice

Move Beyond Policies to Build a Lab Culture Where Safety is Second Nature

Lab Manager October 2025 Cover Image